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ABSTRACT 
An inverse correlation between the morbidity of rheumatoid arthritis and daily intake of 
β-cryptoxanthin has been epidemiologically shown. In this study, we investigated the effects 
of β-cryptoxanthin on the metabolism of cartilage extracellular matrix in vivo and in vitro. 
Oral administration of β-cryptoxanthin (0.1-1 mg/kg) to antigen-induced arthritic rats 
suppressed the loss of glycosaminoglycans in articular cartilage, which is accompanied by the 
interference of aggrecanase-mediated degradation of aggrecan. Inhibition of the interleukin 
1α (IL-1α)-induced aggrecan degradation by β-cryptoxanthin was also observed with porcine 
articular cartilage explants in culture. β-Cryptoxanthin (1-10 µM) dose-dependently 
down-regulated the IL-1α-induced gene expression of aggrecanase 1 (ADAMTS-4) and 
aggrecanase 2 (ADAMTS-5) in cultured human chondrocytes. Moreover, β-cryptoxanthin 
was found to augment the gene expression of aggrecan core protein in chondrocytes. These 
results provide novel evidence that β-cryptoxanthin exerts anti-arthritic actions and suggest 
that β-cryptoxanthin may be useful in blocking the progression of rheumatoid arthritis and 
osteoarthritis. 
 
Keywords: rheumatoid arthritis, osteoarthritis, carotenoid, extracellular matrix, aggrecanase, 
chondrocytes 
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1. Introduction 
Degenerative joint diseases such as rheumatoid arthritis (RA) and osteoarthritis (OA) are 
characterized by cartilage destruction with a loss of its ability to resist compressive and tensile 
forces due to degradation of the extracellular matrix (ECM) [1-3]. Cartilage is a specialized 
connective tissue whose ECM is highly organized having major macromolecules including 
type II collagen, hyaluronan, and aggrecan [4]. Aggrecans are present in cartilage as large 
aggregates interacting with hyaluronan and link proteins, and they are highly hydrated due to 
the negatively charged polysaccharide chains attached to the core proteins. This provides the 
cartilage with its ability to resist compressive loads. On the other hand, type II collagen forms 
a fibrillar meshwork that provides the tissue with tensile strength. These macromolecules 
function to maintain the homeostasis as well as the structural integrity of cartilage. In RA and 
OA, degradation of cartilage ECM exceeds its synthesis due to elevated activity of proteolytic 
enzymes, of which aggrecanases and matrix metalloproteinases (MMPs) are considered to be 
the major effectors [1].   
Increased aggrecanase-dependent aggrecan degradation has been reported to be 
detectable in RA and OA cartilage [2,3]. The expression of aggrecanse-1, a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS)-4, in OA cartilage has been 
reported to correlate with the Mankin score of the disease [5]. On the other hand, 
aggrecanase-2 (ADAMTS-5) is constitutively expressed in human cartilage, but the 
expression of ADAMTS-5 is transiently elevated in human cartilage treated with interleukin 
(IL)-1, which is an inflammatory cytokine for the aggravation of RA and OA [6]. Furthermore, 
the deletion of active ADAMTS-5 in mice has been reported to protect their joints from the 
destruction occurring in the antigen-induced RA model [7], or in the meniscus destabilization 
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model of OA [8], suggesting that aggrecan degradation by ADAMTS-5 is crucial for the 
development of arthritis at least in those animal models. These observations allow us to 
speculate that aggrecanase may become a target molecule for the treatment of RA and OA. At 
the moment, however, clinically effective inhibitors of aggrecanases for RA and OA have not 
been developed [2,3]. 
Currently, treatments to targeting cytokines, including anti-tumor necrosis factor 
α (TNFα) antibodies (Infliximab and Adalimumab), soluble TNF receptor (Etanercept), 
anti-IL-6 receptor antibody (Tocilizumab) and IL-1 receptor antagonist (Anakinra), are widely 
used for RA [9], but these treatments have problems, especially in cost and the increased 
susceptibility to infection [10]. Therefore, therapeutics that can be safely used for a long term 
would be preferable. A few epidemiologic studies [11,12] have shown the inverse correlation 
between morbidity of RA and daily intake of β-cryptoxanthin, suggesting that 
β-cryptoxanthin may prevent the development of RA. β-Cryptoxanthin is a widely distributed 
carotenoid pigment in citrus fruits, and most abundant in Citrus unshiu Marcovich 
(mandarin-orange) [13]. Like other carotenoids,  β-cryptoxanthin exhibits an anti-oxidative 
action. In addition, a portion of intestinally absorbed β-cryptoxanthin has been reported to be 
enzymatically converted to retinoids in intestine and liver by β-carotene-15,15’-oxygenase 
[14]. Furthermore, several biological effects, e.g., an inhibition of carcinogenesis [15], bone 
anabolic activity [16], and an interference with bone resorption [17], have been 
experimentally shown. However, the effects of β-cryptoxanthin on cartilage ECM metabolism 
have not been reported. In this study, we found the inhibitory effects of β-cryptoxanthin on 
cartilage degradation in antigen-induced arthritic rats. Using cultured human articular 
chondrocytes and synovial fibroblasts, we have demonstrated that β-cryptoxanthin prevents 
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aggrecan degradation by oppositely modulating the gene expression of aggrecanases and that 
of aggrecan core protein.  
 
2. Materials and methods 
2.1 Antigen-induced arthritis model 
Female Lewis rats (6 weeks age, body weight 180 to 200 g, Charles River Laboratory Japan, 
Kanagawa, Japan) were immunized 21 and 14 days before induction of antigen-induced 
arthritis (AIA) with 1 mL of a suspension containing 0.5 mL each of methylated bovine serum 
albumin (mBSA) dissolved in phosphate buffered saline (PBS) and Freund’s complete 
adjuvant by multiple subcutaneous injections into both flanks of the animals according to the 
method of Andersson et al. [18]. AIA was induced by intra-articular injection of 0.1 mg 
mBSA in 0.05 mL of PBS into the knee joint cavity. β-Cryptoxanthin (0.1, 0.3, and 1 mg/kg) 
(purity ≥95%; Shikoku Yashima Pure Chemicals, Tokushima, Japan) was orally administered 
to rats once a day starting 1 day before till the 3rd day after AIA induction (Total of 4 days). 
On the day 4 after AIA induction, knee joints were dissected and fixed immediately for 2 days 
in 4% paraformaldehyde, and then decalcified in 22.5% formic acid/10% citric acid for 5 days 
followed by neutralization with 5% sodium sulfate for 1 day. Tissues were then embedded in 
paraffin, and the tissue sections (5 µm) mounted on slides were subjected to toluidine blue 
(pH 4.1)-staining for glycosaminoglycans and immunohistochemical analysis. The animals 
had free access to food and water according to the Guidelines of Experimental Animal Care 
issued by Prime Minister’s Office of Japan. The experimental protocol was approved by the 
Committee of Animal Care and Use of Tokyo University of Pharmacy and Life Sciences. 
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2.3 Immunohistochemical staining 
For immunohistochemical analysis of aggrecan fragments, paraffin sections (5 µm) were 
deparaffinized and heated by microwave oven in 10 mM citrate buffer (pH 6.0) to antigen 
retrieval. Prior to the reaction with antibody, paraffin sections of the joint tissues were 
incubated with 0.1 units/mL of chondroitinase ABC (Seikagaku, Tokyo, Japan) and 0.1 
units/mL of keratanase (Seikagaku) in 20 mM Tris-HCl (pH 7.4) containing 150 mM NaCl at 
37°C for 1 h to digest the polysaccharide chains of aggrecan. Tissue sections were reacted 
with the antibody that recognizes the aggrecanase-cleaved C-terminal neoepitope amino acid 
sequence GGNITEGE of aggrecan core protein (Thermo Fisher Scientific, Kanagawa, Japan) 
as a primary antibody overnight at 4°C followed by a reaction with horseradish 
peroxidase-conjugated goat anti-rabbit IgG (Nichirei Biosciences, Tokyo, Japan) as a 
secondary antibody for 30 min at room temperature. After incubation with the secondary 
antibody, the sections were stained with 3,3-diaminobenzidine (Sigma Chemical, St. Louis, 
MO). For the control staining, non-immune rabbit IgG was used instead of the primary 
antibody. Positive immunohistochemical staining in a constant area of articular cartilage was 
calculated using a computer software for imaging analysis, Lumina vision (Mitani, Fukui, 
Japan). 
 
2.4 Cell culture 
Normal human articular chondrocytes (Cambrex Bio Science Walkersville, Walkersville, MD) 
were encapsulated in alginate beads and cultured in Dulbecco’s modified Eagle’s 
medium-F12 (DMEM-F12) (Invitrogen, Carlsbad, CA) in the presence of 10% fetal bovine 
serum (FBS) (Thermo ELECTRON, Melbourne, Australia) and antibiotics [100 units/ml of 
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penicillin G (MP Biomedicals, solon, OH) and 100 µg/ml of streptomycin sulfate (Meiji Seika, 
Tokyo, Japan)]. Briefly, chondrocytes were suspended in 1.2% alginate/0.15 M NaCl at the 
density of 4 x 106 cells/mL, and the cell suspension was dropped into 102 mM CaCl2 solution 
under stirring to form alginate beads. The alginate beads were washed several times with 0.15 
M NaCl, and then cells embedded in alginate beads were cultured for 7 days in DMEM-F12 
with 10% FBS, the antibiotics, and 50 µM ascorbic acid-2 phosphate in 24-multiwell plates (4 
beads/well), and then treated for 6 days with IL-1α (10 ng/ml) (R&D Systems, Minneapolis, 
MN) and/or β-cryptoxanthin (1 to 10 µM) in DMEM-F12 with 0.2% lactalbumin hydrolysate 
(LAH) (Sigma Chemical), the antibiotics and 50 µM ascorbic acid-2 phosphate. 
β-Cryptoxanthin was dissolved in dimethylsulfoxide (DMSO) (Sigma Chemical), and the 
final concentration of DMSO was 0.1 % in all cultures. The harvested culture medium and 
cell lysate were stored at -20 °C until use. 
 
2.5 RNA extraction and quantitative real-time reverse transcription (RT)-PCR 
The total RNA (1 µg) isolated from cells using Isogen (Nippon Gene, Tokyo, Japan) was 
subjected to RT reaction using a QuantiTect Reverse Transcription kit (Qiagen, Tokyo, Japan) 
according to the manufacturer’s instruction. An aliquot of the RT reaction products (an 
equivalent of 25 ng of total RNA) was subjected to real-time PCR using a QuantiTect SYBR 
Green PCR kit (Qiagen) and a QuantiTect Primer Assays [Cat No. QT00032949 for human 
ADAMTS-4, Cat No. QT00011088 for human ADAMTS-5, Cat No. QT00001365 for human 
aggrecan core protein, and Cat No. QT00079247 for human glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH)] (Qiagen). PCR was performed using ABI PRISM 7000 sequence 
detection system (Applied Biosystems, Tokyo, Japan) under the following conditions, 
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denature at 94 °C for 15 s, annealing at 55 °C for 30 s, and extension at 72 °C for 30 s. 
Relative expression level was calculated by ∆∆CT methods with the CT value of GAPDH. 
 
2.6 Measurement of aggrecanase activity in porcine cartilage explants 
Aggrecanase activity was determined using porcine cartilage explant culture as previously 
described [19]. Total glycosaminoglycan (GAG) released from the cartilage explants into the 
conditioned media was measured using a modification of the dimethylmethylene blue assay 
[20].  
 
2.7 Detection of aggrecan fragments 
Aggrecan fragments caused by aggrecanase were analyzed by Western blotting using a mouse 
monoclonal antibody [BC-3] against the N-terminal neoepitope ARGSV of aggrecan 
generated by aggrecanase (a gift from Dr. C. Hughes from University of Cardiff), as described 
previously [21]. Immunoreactive aggrecan neoepitope (ARGSV) was visualized with 
enhanced chemiluminescence-Western-blotting detection reagents (GE Healthcare 
Bio-Sciences, Tokyo, Japan) using an Image Analyzer LAS-1000 Plus (GE Healthcare 
Bio-Sciences) according to the manufacturer’s instructions. 
 
2.8 Statistical analysis 
A one-way ANOVA was performed using StatView version 5.0 (SAS Institute, SAS Campus 
Drive Cary, NC) for the data analysis. Independent student’s t-test was applied for pair 
comparisons, and Fisher’s PLSD post-hoc test was performed for multiple comparisons. 
P-value less than 0.05 was considered significant difference. 
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3. Results 
3.1 Anti-arthritic action of β-cryptoxanthin in antigen-induced arthritic rats 
To investigate the anti-arthritic action of β-cryptoxanthin, AIA rats were used as an arthritic 
disease model [18], and the knee joints were histologically evaluated. Poorly stained signals 
by toluidine blue were detected in AIA rats compared with untreated control rats, indicating 
the loss of glycosaminoglycans (GAG) (Fig. 1A vs. B). Orally administered β-cryptoxanthin 
interfered with the loss of GAG in a dose-dependent manner (Figs. 1C-E vs. B). 
Immunohistochemical staining with the antibody recognizing the C-terminal neoepitope 
NITEGE sequence of aggrecan showed an increased aggrecanase-dependent fragmentation of 
aggrecan in AIA rat, which were largely localized with chondrocytes (Fig. 1F vs. G). The 
treatment of the AIA rats with β-cryptoxanthin suppressed the generation of NITEGE 
fragments (Figs. 1H-J vs. G). Imaging analysis of immunostained NITEGE fragments 
revealed that β-cryptoxanthin dose-dependently decreased aggrecan degradation in AIA rats 
(Fig. 1K). These observations suggested that β-cryptoxanthin exerts an anti-arthritic action 
through interference with the aggrecanase-mediated aggrecan degradation. 
 
3.2 β-Cryptoxanthin blocks IL-1α-induced aggrecan degradation in porcine cartilage 
Next, we examined whether β-cryptoxanthin affects aggrecan degradation in cartilage 
stimulated with IL-1α. As shown in Fig. 2A, β-cryptoxanthin dose-dependently suppressed 
the IL-1α-augmented GAG release from porcine articular cartilage. Western blot analysis also 
revealed that β-cryptoxanthin decreased the amount of N-terminal neoepitope ARGSV of 
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aggrecan generated by the IL-1α-induced aggrecanase activity (Fig. 2B). There were no 
detectable aggrecan fragments produced by MMPs under these experimental conditions (Fig. 
S1). These observations suggest that β-cryptoxanthin blocks the aggrecan degradation in 
cartilage by decreasing aggrecanase activity. 
 
3.3 Effects of β-cryptoxanthin on the gene expression of ADAMTSs-4 and -5, and aggrecan 
core protein in human articular chondrocytes 
To clarify the effect of β-cryptoxanthin on the gene expression of ADAMTSs-4 and -5 in 
articular chondrocytes, human articular chondrocytes encapsulated in alginate beads were 
treated with IL-1α in the presence or absence of β-cryptoxanthin. As shown in Fig. 3A, 
β-cryptoxanthin suppressed the IL-1α-induced gene expression of ADAMTSs-4 and -5 in a 
dose-dependent manner (upper and lower panels, respectively). Tissue inhibitor of 
metalloproteinases 3 (TIMP-3) inhibits the enzymatic activity of ADAMTSs-4 and -5 [22], 
but there were no significant changes in the mRNA level of TIMP-3 in the 
β-cryptoxanthin-treated chondrocytes (Fig. 3B). On the other hand, IL-1α slightly decreased 
the mRNA levels of aggrecan core protein in chondrocytes, but β-cryptoxanthin augmented 
the gene expression of aggrecan core protein above the level of the control chondrocytes (Fig. 
3C). Taken together, these results suggest that β-cryptoxanthin protects cartilage from 
degradation by suppressing the gene expression of ADAMTSs-4 and -5 and augmenting that 
of aggrecan core protein in human articular chondrocytes. 
 
4. Discussion 
Aggrecanases play central roles in both physiological and pathological catabolism of cartilage 
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matrix [2,3], and ADAMTS-4 is considered to participate in the degradation of ECM 
molecules in joint tissues, including those in cartilage and ligaments. Therefore, the 
suppression of ADAMTS expression is considered to be an effective way to block the 
cartilage destruction in RA and OA [2,3]. 
The expression of ADAMTSs-4 and ADAMTS-5 mRNAs is induced by IL-1, TNFα, 
the combination of IL-1 and oncostatin M, or transforming growth factor-β [6,23], whereas 
n-3 fatty acids [24] and fibroblasts growth factor 2 [6] suppress of the expression of 
ADAMTS-4 and ADAMTS-5, respectively. A few natural organic compounds have been 
reported to block the inflammatory cytokine-induced production of ADAMTSs in 
chondrocytes or synovial fibroblasts. For example, triptolide from the Chinese herb, 
Tripterygium wilfordii Hook F suppresses the expression of ADAMTS-4 in chondrocytes [25], 
and nobiletin, a citrus polymethoxy flavonoid, blocks the expression of ADAMTSs-4 and -5 
in collagen-induced arthritic mice model [26]. β-Cryptoxanthin described here is a novel 
natural compound that prevents cartilage destruction both in-vitro and in-vivo models of 
arthritis. The efficacy of the orally administered β-cryptoxanthin in blocking cartilage 
destruction in the rat AIA model suggests its potential as an anti-arthritic agent in OA and RA.  
Regarding the control of enzymatic activity of aggrecanases, TIMP-3 has been reported 
to be an important cartilage protectant due to the inhibition of ADAMTSs-4 and -5 activity 
[22]. In this study, we have demonstrated that β-cryptoxanthin suppressed the IL-1α-induced 
gene expression of ADAMTSs-4 and -5 in human chondrocytes, but it did not alter the gene 
expression of TIMP-3 in human chondrocytes. On the contrary, we found that 
β-cryptoxanthin augments the gene expression of aggrecan core protein in human 
chondrocytes. Aggrecan is the most abundant proteoglycan in cartilage, and 
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aggrecanase-mediated degradation of aggrecan is observed at the initial phase of cartilage 
destruction [1-3], which makes collagen fibrils more susceptible to collagenases [27]. 
Therefore, the augmentation of aggrecan biosynthesis shifts cartilage metabolism towards the 
anabolic state. Together, these results indicate that β-cryptoxanthin prevents cartilage from 
catabolism and helps to maintain homeostasis of the cartilage tissue.  
It has been reported that the serum concentration of β-cryptoxanthin is approximately 
0.1 to 0.2 µM, whereas more than 1 µM is detectable in Japanese inhabitants who usually take 
Citrus unshiu Marcovich [28,29]. Thus, our findings support the epidemiological studies 
reporting an inverse correlation between the morbidity of RA and the daily intake of 
β-cryptoxanthin. In contrast, the daily intake of other carotenoid pigments does not correlate 
with the incidence of RA [11,12]. We have presented preliminary data demonstrating that 
β-carotene and astaxanthin suppressed the gene expression of ADAMTS-4, but not that of 
ADAMTS-5, while β-cryptoxanthin decreased the mRNA level of both ADAMTSs-4 and -5 
in cultured human synovial fibroblasts (Fig. S2). Furthermore, since ADAMTS-5 has been 
shown to be the major aggrecanase, at least in mouse arthritis models [7,8], the blocking 
effect of β-cryptoxanthin on ADAMTS-5 expression may be a key factor related to the 
morbidity of RA.  
Orally administered β-cryptoxanthin has been reported to be partially converted to 
retinoids by β-carotene-15,15’-oxygenase [14], which thereby exhibits provitamin A activity. 
Although retinoic acid has been reported to up-regulate the expression of ADAMTS-5 mRNA 
[30], we have found that all-trans retinoic acid (1 µM) did not influence the gene expression 
of ADAMTS-5 but suppressed that of ADAMTS-4 in human synovial fibroblasts (Fig. S3). 
Furthermore, we conclude that β-cryptoxanthin is the molecule that suppresses ADAMTS-5 
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expression, but further experiments are necessary to clarify the transcriptional regulatory 
mechanism of β-cryptoxanthin. 
In conclusion, we have provided novel evidence that β-cryptoxanthin exerts 
chondroprotective actions by inhibition of aggrecan degradation by suppressing ADAMTSs-4 
and -5 expression and augmenting aggrecan synthesis in vivo and in vitro. Our study sheds 
light on the molecular mechanism behind the epidemiologic observation that daily intake of 
β-cryptoxanthin reduces the morbidity of RA. 
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Figure legends 
Fig. 1. Effects of β-cryptoxanthin on cartilage destruction in AIA rats. β-Cryptoxanthin 
(β-CRX) (0.1, 0.3, and 1 mg/kg) was orally administrated to rats once a day starting from 1 
day before till the 3rd day after AIA induction. Knee joints were dissected, and the tissue 
sections (5 µm) mounted on slides were subjected to toluidine blue (pH 4.1)-staining and 
immunohistochemical analysis using the antibody that recognize the aggrecanase-cleaved 
C-terminal neoepitople amino acid sequence NITEGE of aggrecan core protein. [A]-[E]: 
toluidine blue (pH 4.1)-staining and [F]-[J]: immunohistochemical staining for the 
aggrecanase-cleaved fragments with anti-NITEGE antibody. [K]: Positive 
immunohistochemical staining in a constant area of articular cartilage was calculated by 
imaging analysis, and data represent as mean ± SEM for 3 animals. Arrows indicate the 
surface of cartilage. Bars indicate 100 µm. *, significantly different from control (Normal) 
(p<0.05). #, significantly different from AIA treatment (p<0.05). 
 
Fig. 2. β-Cryptoxanthin interferes with IL-1α-induced aggrecan degradation in cultured 
porcine cartilage explants. Porcine articular cartilage explants were treated with IL-1α (10 
ng/ml) in the presence or absence of β-cryptoxanthin (β-CRX) (0.01 to 1 µM) for 48 h. [A]: 
total GAG released into the conditioned medium was measured by the DMMB assay as 
described in the text. [B]: aggrecan fragments generated by aggrecanase activity were 
detected by Western blot analysis using BC-3 antibody against N-terminal neoepitope 
ARGSV of aggrecan generated by aggrecanase. Data represent the mean ± SEM. ***, 
significantly different from the untreated control cells (p<0.001). #, ##, and ###, significantly 
different from the cells treated with IL-1α (p<0.05, 0.01, and 0.001, respectively). 
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Fig. 3. Effect of β-cryptoxanthin on the gene expression of ADAMTSs-4 and -5, TIMP-3, and 
aggrecan core protein in human articular chondrocytes. Human chondrocytes embedded in 
alginate beads at the 5th passage were treated for 6 days with IL-1α (10 ng/ml) in the 
presence or absence of β-cryptoxanthin (β-CRX) (1, 5, and 10 µM). Total RNA was subjected 
to quantitative real-time RT-PCR for ADAMTSs-4 and -5 [A], TIMP-3 [B], and aggrecan core 
protein [C] as described in the text. Relative expression is shown by taking IL-1α-treated cells 
(lane 2) as 1 after normalized by GAPDH mRNA. Data represent the mean ± SEM for 3 
independent experiments. * and ***, significantly different from the untreated cells (p<0.05 
and 0.001, respectively). #, ##, and ###, significantly different from the cells treated with 
IL-1α (p<0.05, 0.01, and 0.001, respectively). 
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Highlights 
 β-Cryptoxanthin blocks the aggrecan degradation in cartilage by decreasing aggrecanase 
activity in vivo. 
 β-Cryptoxanthin down-regulates the expression of aggrecanase 1 (ADAMTS-4) and 
aggrecanase 2 (ADAMTS-5) in human chondrocytes.  
 β-Cryptoxanthin augments the expression of aggrecan core protein in human chondrocytes.  
